Key statistics
As of last trade, Shanghai Junshi Biosciences Co Ltd (1877:HKG.HS) traded at 13.60, 48.31% above the 52 week low of 9.17 set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.26 |
---|---|
High | 13.64 |
Low | 12.96 |
Bid | 13.58 |
Offer | 13.60 |
Previous close | 13.24 |
Average volume | 1.76m |
---|---|
Shares outstanding | 985.69m |
Free float | 150.34m |
P/E (TTM) | -- |
Market cap | 28.04bn HKD |
EPS (TTM) | -2.14 HKD |
Data delayed at least 15 minutes, as of Nov 05 2024.
More ▼
Announcements
- Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR
- Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
- Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
- Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
- Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
- Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
- Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
More ▼